itzhak_krinsky

Teva announces appointment of Prof Itzhak Krinsky

pharmafile | September 20, 2012 | Appointment | Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Itzhak Krinsky, Teva 

Teva has announced the appointment of Professor Itzhak Krinsky as chairman of Teva Japan and Teva South Korea and head of Business Development Asia-Pacific.

Currently serving as executive vice president, Corporate Business Development at Teva, Krinsky’s new appointment will be effective from October when he will be responsible for overseeing Teva’s generic and branded pharma businesses in Japan and South Korea.

Additionally, Krinsky will manage Business Development for the Asia-Pacific region. He will continue to serve as a member of the Teva Executive Committee and will be located in Tokyo.

Advertisement

Krinsky will replace Moshe Manor, president and chief executive of Teva Asia- Pacific who decided to retire. There will be a gradual and orderly transition period until the end of the year to ensure business continuity and Krinsky will report directly to Jeremy Levin, the firm’s president and chief executive.

“As part of our global strategic plan and in response to our growing presence in Asia-Pacific, we are positioning this part of our business to focus on the strong growth prospects in this region,” said Levin.

“It is a privilege and a pleasure for me to be a part of these vibrant and dedicated regional teams,” added Krinsky.

Related Content

Teva announces positive results from trial of AJOVY for migraine

Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its …

louis-reed-pwckf7l4-no-unsplash_5

Sanofi and Teva partner for development of inflammatory bowel disease treatment

Sanofi and Teva Pharmaceuticals have announced that they will collaborate for the co-development and co-commercialisation …

judge-gavel-1461966002dbr

Teva’s cancer drug Bendeka protected from generics until 2031, judge rules

A US federal judge has ruled that generic versions of the cancer treatment Bendeka infringe …

The Gateway to Local Adoption Series

Latest content